Purchase of capital assets (49,526) (234,919)
Purchase of intangible assets (345,425)
Proceeds on disposal of capital assets 60,754 3,573
Net cash received under contractual arrangement 400,000 475,000
Cash received on acquisition of ENI - 1,040,471
ENI acquisition costs - (253,296)
Cash received on acquisition of NMX 109,730 -
NMX acquisition costs (322,842) -
-------------------------------------------------------------------------
Cash provided by (used in) investing
activities (21,941,808) 2,911,124
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Proceeds from bought deal financing, net - 9,648,600
Repayment of long term debt (300,707) (2,740,795)
Repayment of obligation under capital leases - (17,019)
Proceeds from issuance of common shares, net 24,345,142 8,016
-------------------------------------------------------------------------
Cash provided by (used in) financing
activities 24,044,435 6,898,802
-------------------------------------------------------------------------
Net increase (decrease) in cash and cash
equivalents during the period (2,697,195) (2,523,639)
Cash and cash equivalents, beginning of
period 4,074,582 6,598,221
-------------------------------------------------------------------------
Cash and cash equivalents, end of period 1,377,387 4,074,582
-----------------------------------
'/>"/>
| SOURCE Transition Therapeutics Inc. Copyright©2007 PR Newswire. All rights reserved |